Including $0.8M From Recent Warrant Exercise
GRI Bio Raises $13.9M In Gross Proceeds Since Start Of 2024; Funds Expected To Extend Cash Runway Into Mid-Q1 2025, Supporting Interim Data From Phase 2a Study Of GRI-0621 For Idiopathic Pulmonary Fibrosis (IPF) Treatment
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.